<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Vaxil Bio Ltd.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/xg-uLJLg0vJnYRIeR2Qx6g==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2024, Vaxil Bio Ltd.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Wed, 21 Aug 2024 12:09:12 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/08/21/2933473/0/en/Vaxil-Bio-Enters-Into-Definitive-Agreement-With-Green-Data-Centers-for-Reverse-Take-Over.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/08/21/2933473/0/en/Vaxil-Bio-Enters-Into-Definitive-Agreement-With-Green-Data-Centers-for-Reverse-Take-Over.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over</title>
      <description><![CDATA[<p align="justify"><strong><em>Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws.</em></strong></p>]]></description>
      <pubDate>Wed, 21 Aug 2024 12:09 GMT</pubDate>
      <dc:identifier>2933473</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 21 Aug 2024 12:09 GMT</dc:modified>
      <dc:subject>Mergers and Acquisitions</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/27/2888434/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Green-Data-in-Respect-of-A-Proposed-Reverse-Takeover.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/05/27/2888434/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Green-Data-in-Respect-of-A-Proposed-Reverse-Takeover.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover</title>
      <description><![CDATA[<p align="left"><strong><em>Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States</em></strong><br></p>]]></description>
      <pubDate>Mon, 27 May 2024 10:30 GMT</pubDate>
      <dc:identifier>2888434</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Mon, 27 May 2024 10:30 GMT</dc:modified>
      <dc:subject>Changes in company's own shares</dc:subject>
      <dc:subject>Major shareholder announcements</dc:subject>
      <dc:subject>Mergers and Acquisitions</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/03/04/2839727/0/en/Vaxil-Bio-Proposed-Reverse-Takeover-with-Copper-Bullet-Terminated-and-Update-of-Research-Activities.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/03/04/2839727/0/en/Vaxil-Bio-Proposed-Reverse-Takeover-with-Copper-Bullet-Terminated-and-Update-of-Research-Activities.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated and Update of Research Activities</title>
      <description><![CDATA[<p align="justify"><strong><em>Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States</em></strong></p>]]></description>
      <pubDate>Mon, 04 Mar 2024 14:57 GMT</pubDate>
      <dc:identifier>2839727</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Mon, 04 Mar 2024 14:58 GMT</dc:modified>
      <dc:subject>Mergers and Acquisitions</dc:subject>
      <dc:subject>Major shareholder announcements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/10/2807452/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Copper-Bullet-Mines-in-Respect-of-a-Proposed-Reverse-Takeover.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/01/10/2807452/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Copper-Bullet-Mines-in-Respect-of-a-Proposed-Reverse-Takeover.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Bio Enters Into Letter of Intent With Copper Bullet Mines in Respect of a Proposed Reverse Takeover</title>
      <description><![CDATA[<p align="justify"><strong><em>Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States</em></strong></p>]]></description>
      <pubDate>Wed, 10 Jan 2024 20:01 GMT</pubDate>
      <dc:identifier>2807452</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 10 Jan 2024 20:02 GMT</dc:modified>
      <dc:subject>Mergers and Acquisitions</dc:subject>
      <dc:subject>Corporate Action</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/08/02/2717467/0/en/Vaxil-Provides-Update-on-Research-Activities-and-Management-Changes.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/08/02/2717467/0/en/Vaxil-Provides-Update-on-Research-Activities-and-Management-Changes.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Provides Update on Research Activities and Management Changes</title>
      <description><![CDATA[<p align="justify">NESS-ZIONA, Israel, Aug.  02, 2023  (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("<strong>Vaxil</strong>" or the "<strong>Company</strong>") (TSX VENTURE:VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases announces the follow update on its research activities and changes in senior management.<br></p>]]></description>
      <pubDate>Wed, 02 Aug 2023 21:00 GMT</pubDate>
      <dc:identifier>2717467</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 02 Aug 2023 21:00 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
      <dc:subject>Changes in company's own shares</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/04/24/2653458/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/04/24/2653458/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil’s Annual and Special Shareholders Meeting</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Mon, 24 Apr 2023 23:50 GMT</pubDate>
      <dc:identifier>2653458</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Mon, 24 Apr 2023 23:50 GMT</dc:modified>
      <dc:subject>Annual Meetings &amp; Shareholder Rights</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/03/07/2397873/0/en/Vaxil-Provides-Update-on-Research-Activities.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/03/07/2397873/0/en/Vaxil-Provides-Update-on-Research-Activities.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Provides Update on Research Activities </title>
      <description><![CDATA[<p align="left">Not for distribution by US newswire or in United States</p>]]></description>
      <pubDate>Mon, 07 Mar 2022 12:50 GMT</pubDate>
      <dc:identifier>2397873</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Mon, 07 Mar 2022 12:50 GMT</dc:modified>
      <dc:subject>Research Analysis and Reports</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/02/08/2381423/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/02/08/2381423/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil’s Annual and Special Shareholders Meeting</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Tue, 08 Feb 2022 22:30 GMT</pubDate>
      <dc:identifier>2381423</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Tue, 08 Feb 2022 22:30 GMT</dc:modified>
      <dc:subject>Annual Meetings &amp; Shareholder Rights</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/01/04/2360965/0/en/Vaxil-Provides-Final-Results-on-Its-Previously-Disclosed-Research-With-Ben-Gurion-University-of-the-Negev.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/01/04/2360965/0/en/Vaxil-Provides-Final-Results-on-Its-Previously-Disclosed-Research-With-Ben-Gurion-University-of-the-Negev.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Provides Final Results on Its Previously Disclosed Research With Ben-Gurion University of the Negev</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Tue, 04 Jan 2022 15:02 GMT</pubDate>
      <dc:identifier>2360965</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Tue, 04 Jan 2022 15:02 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/12/13/2351189/0/en/Vaxil-Announces-Resignation-of-Director.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/12/13/2351189/0/en/Vaxil-Announces-Resignation-of-Director.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces Resignation of Director</title>
      <description><![CDATA[Not for distribution by US newswire or in United States <pre>Not for distribution by US newswire or in United States</pre>]]></description>
      <pubDate>Mon, 13 Dec 2021 21:30 GMT</pubDate>
      <dc:identifier>2351189</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Mon, 13 Dec 2021 21:30 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/11/12/2333670/0/en/Vaxil-Announces-Change-of-Auditor.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/11/12/2333670/0/en/Vaxil-Announces-Change-of-Auditor.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces Change of Auditor</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States</p>]]></description>
      <pubDate>Fri, 12 Nov 2021 22:10 GMT</pubDate>
      <dc:identifier>2333670</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Fri, 12 Nov 2021 22:10 GMT</dc:modified>
      <dc:subject>Press releases</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/11/11/2332560/0/en/Vaxil-Provides-Update-on-Acquisition-of-Short-Wave-Pharma-Inc.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/11/11/2332560/0/en/Vaxil-Provides-Update-on-Acquisition-of-Short-Wave-Pharma-Inc.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Provides Update on Acquisition of Short Wave Pharma Inc.</title>
      <description><![CDATA[Not for distribution by US newswire or in United States <pre>Not for distribution by US newswire or in United States</pre>]]></description>
      <pubDate>Thu, 11 Nov 2021 12:55 GMT</pubDate>
      <dc:identifier>2332560</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Thu, 11 Nov 2021 12:55 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Mergers and Acquisitions</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/10/14/2314478/0/en/Vaxil-Signs-Letter-of-Intent-to-Acquire-a-100-Interest-in-Short-Wave-Pharma-Inc.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/10/14/2314478/0/en/Vaxil-Signs-Letter-of-Intent-to-Acquire-a-100-Interest-in-Short-Wave-Pharma-Inc.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Signs Letter of Intent to Acquire a 100% Interest in Short Wave Pharma Inc.</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Thu, 14 Oct 2021 14:52 GMT</pubDate>
      <dc:identifier>2314478</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Thu, 14 Oct 2021 14:53 GMT</dc:modified>
      <dc:subject>Mergers and Acquisitions</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/10/12/2312710/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/10/12/2312710/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces Progress on Research and Development Activities  </title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Tue, 12 Oct 2021 13:07 GMT</pubDate>
      <dc:identifier>2312710</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Tue, 12 Oct 2021 13:08 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/6d473cdd-5542-4a4e-a776-f30bc192e974">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2021/10/12/2312710/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html">
    <img src="https://ml.globenewswire.com/Resource/Download/6d473cdd-5542-4a4e-a776-f30bc192e974" width="600" align="left" border="0" alt="Figure 1" title="In vivo mice survival in experimental CRC liver metastasis model" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/09/29/2305285/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/09/29/2305285/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces Progress on Research and Development Activities</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Wed, 29 Sep 2021 11:50 GMT</pubDate>
      <dc:identifier>2305285</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 29 Sep 2021 11:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/08/04/2274478/0/en/Vaxil-Announces-Changes-to-Senior-Management-and-Provides-Updates-on-Current-Research-and-Development-Work.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/08/04/2274478/0/en/Vaxil-Announces-Changes-to-Senior-Management-and-Provides-Updates-on-Current-Research-and-Development-Work.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces Changes to Senior Management and Provides Updates on Current Research and Development Work</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Wed, 04 Aug 2021 11:50 GMT</pubDate>
      <dc:identifier>2274478</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 04 Aug 2021 11:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Directors and Officers</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/05/31/2238803/0/en/Vaxil-Provides-Research-and-Development-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/05/31/2238803/0/en/Vaxil-Provides-Research-and-Development-Update.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Provides Research and Development Update</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Mon, 31 May 2021 11:50 GMT</pubDate>
      <dc:identifier>2238803</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Mon, 31 May 2021 11:50 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/05/05/2223943/0/en/Vaxil-Announces-CEO-Resignation.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/05/05/2223943/0/en/Vaxil-Announces-CEO-Resignation.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces CEO Resignation</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Wed, 05 May 2021 21:00 GMT</pubDate>
      <dc:identifier>2223943</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 05 May 2021 21:00 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/03/11/2191688/0/en/Vaxil-Announces-2021-Reseach-and-Development-Strategy-and-Progress.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/03/11/2191688/0/en/Vaxil-Announces-2021-Reseach-and-Development-Strategy-and-Progress.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Announces 2021 Reseach and Development Strategy and Progress</title>
      <description><![CDATA[Not for distribution by US newswire or in United States <pre>Not for distribution by US newswire or in United States</pre>]]></description>
      <pubDate>Thu, 11 Mar 2021 20:51 GMT</pubDate>
      <dc:identifier>2191688</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Thu, 11 Mar 2021 20:51 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2021/02/17/2177422/0/en/Vaxil-Provides-Strategy-Update-From-Conclusion-of-COVID-19-Challenge-Study.html</guid>
      <link>https://www.globenewswire.com/news-release/2021/02/17/2177422/0/en/Vaxil-Provides-Strategy-Update-From-Conclusion-of-COVID-19-Challenge-Study.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:VXL</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA92243L1076</category>
      <title>Vaxil Provides Strategy Update From Conclusion of COVID-19 Challenge Study</title>
      <description><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></description>
      <pubDate>Wed, 17 Feb 2021 18:25 GMT</pubDate>
      <dc:identifier>2177422</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Vaxil Bio Ltd.</dc:contributor>
      <dc:modified>Wed, 17 Feb 2021 18:25 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
  </channel>
</rss>